4 ms·

See here: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-1... G

See here: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-1... Going from zero to preclinical is about 1/3 of the costs of going from preclinical to phase 2. Phase 3 is not part of this study, neither is parallel production.

adriancr 6y ago
That is a study of existing vaccines based on existing practices (which result in astrazeneca's 70% effective vaccine) BioNTech is a different vaccine type, hence effectiveness and fact that both moderna and pfizer license it. The fact that Germany subsidised the last stages to speed it up doesnt mean technology should be public access. That's for the government and company to negotiate.